Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

Durata Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

March 22, 2012

MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the proposed offering, with RBC Capital Markets, LLC and Wedbush PacGrow Life Sciences acting as co-managers. The number of shares to be offered and the price range for the proposed offering have not yet been determined.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained by contacting BofA Merrill Lynch, 4 World Financial Center, New York, NY 10080, Attn: Prospectus Department, or via email, at [email protected] or Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone 800-221-1037, or via email, at [email protected]

About Durata Therapeutics, Inc.

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata is developing its advanced-stage lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections.

Contacts

Media
Burns McClellan
Justin Jackson, 212-213-0006
[email protected]
or
Company
Durata Therapeutics
Corey Fishman, 973-993-4865
Chief Operating Officer
[email protected]

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.